Prehliadač alebo jeho nastavenia nie sú podporované.

Praktik.ai používa moderné webové technológie kvôli bezpečnosti, rýchlosti a spoľahlivému prihlasovaniu. Tento prehliadač ich nepodporuje alebo blokuje JavaScript, preto sa aplikácia nemusí správne načítať.

Aktualizujte prosím Chrome, Edge, Firefox alebo Safari na najnovšiu verziu a stránku potom obnovte.

Ak používate Windows 7, Windows 8 alebo Windows 8.1, Chrome a Edge už nemusia ponúkať novú verziu. V takom prípade použite novšie zariadenie alebo kontaktujte podporu Praktik.ai.

Prohlížeč nebo jeho nastavení nejsou podporované.

Praktik.ai používá moderní webové technologie kvůli bezpečnosti, rychlosti a spolehlivému přihlašování. Tento prohlížeč je nepodporuje nebo blokuje JavaScript, proto se aplikace nemusí správně načíst.

Aktualizujte prosím Chrome, Edge, Firefox nebo Safari na nejnovější verzi a stránku potom obnovte.

Pokud používáte Windows 7, Windows 8 nebo Windows 8.1, Chrome a Edge už nemusí nabízet novou verzi. V takovém případě použijte novější zařízení nebo kontaktujte podporu Praktik.ai.

Your browser or its settings are not supported.

Praktik.ai uses modern web technologies for security, speed, and reliable sign-in. This browser does not support them, or JavaScript is blocked, so the app may not load correctly.

Please update Chrome, Edge, Firefox, or Safari to the latest version and then reload this page.

If you use Windows 7, Windows 8, or Windows 8.1, Chrome and Edge may no longer offer a newer version. In that case, use a newer device or contact Praktik.ai support.

Not effective Commission Decision

Rozhodnutie č. 296/2003

Important dates

Declared: 28. apríla 2003
Approved: 28. apríla 2003
Effective from: 1. mája 2003
Effective until: 16. apríla 2006

Documents and links

Commission Decision

of 28 April 2003

appointing members of the Committee for Orphan Medicinal Products

(Text with EEA relevance)

(2003/296/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products(1), and in particular Article 4(3) thereof,

Whereas:

(1) The term of office of the members of the Committee for Orphan Medicinal Products, hereinafter "the Committee" set up in accordance with Article 4 of Regulation (EC) No 141/2000 expires on 15 April 2003. It is necessary, therefore, to appoint a new member and to renew the terms of office of certain existing members.

(2) The European Agency for the Evaluation of Medicinal Products has recommended three persons for nomination.

(3) The members of the Committee should be appointed for a period of three years starting on 16 April 2003,

HAS DECIDED AS FOLLOWS:

Article 1

1. The following is hereby appointed member of the Committee for Orphan Medicinal Products, hereinafter referred to as "the Committee", to represent patients' organisations for a term of three years, from 16 April 2003:

Birthe Holm.

2. The following are hereby reappointed members of the Committee to represent patients' organisations for a term of three years, from 16 April 2003:

Yann Le Cam

Alastair Kent.

Article 2

On the recommendation of the European Agency for the Evaluation of Medicinal Products, the following are hereby reappointed members of the Committee for a term of three years, from 16 April 2003:

Dr Eric Abadie

Dr David Lyons

Prof. Gianmartino Benzi.

Done at Brussels, 28 April 2003.

For the Commission

Erkki Liikanen

Member of the Commission

(1) OJ L 18, 22.1.2000, p. 1.